BOSTON, Nov. 5, 2011 /PRNewswire/ -- C1-esterase inhibitor (C1-INH) concentrate at 20 U/kg is a safe and effective therapy for the long-term treatment of successive acute swelling attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to final data presented at the 2011 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. Additional data presented at the meeting confirms that C1-INH concentrate provided consistent and reliable treatment response in patients treated for multiple successive HAE attacks at any body location.
The final results from the prospective, open label International Multi-center Prospective Angioedema C1-Inhibitor Trial (I.M.P.A.C.T. 2) with C1-INH concentrate showed a median time to the onset of symptom relief of 0.46 hours which was similar for all types of attacks, including laryngeal, abdominal, peripheral and facial. The median time for complete resolution was 15.5 hours.
"The final I.M.P.A.C.T. 2 results provide conclusive clinical evidence that C1-INH replacement therapy should be considered the first-line therapy in the on-demand treatment of acute swelling attacks of hereditary angioedema," said Timothy J. Craig, D.O., Professor of Medicine and Pediatrics at Penn State University in Hershey, PA. "These compelling data reflect the outcomes of 1,085 HAE attacks, the largest number of HAE attacks treated in a prospective study, and show that C1-INH concentrate is highly and consistently effective, safe and well-tolerated in rapidly relieving symptoms of HAE at many different regions of the body, with no rebound effects. In fact, 99 percent of all attacks were successfully treated with a single dose of 20U/kg."
The effect of repeated treatment on the efficacy of C1-INH was also assessed in an analysis of 18 patients who were treated for at least 15 attacks. Results showed that th
|SOURCE CSL Behring|
Copyright©2010 PR Newswire.
All rights reserved